Life-Threatening Thrombosis Complicating the Management of Hepatic Hemorrhage: Anticoagulant Treatment in a Newborn with Hemophilia B

Journal of Pediatric Hematology/Oncology

Volumn 26, Issue 4, 2004, Pages 258-263

  Douvas, Michael Gregory ^a,b   Monahan, Paul Edward ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NORTH CAROLINA HOSPITALS   (United States)

Author keywords

Anticoagulation; Hemophilia B; Liver hemorrhage; Sinovenous thrombosis; Superior vena cava syndrome

Indexed keywords

ALPHA 2 ANTIPLASMIN; ANTICOAGULANT AGENT; ANTICONVULSIVE AGENT; BLOOD CLOTTING FACTOR 5 LEIDEN; BLOOD CLOTTING FACTOR 8; CARDIOLIPIN ANTIBODY; ENOXAPARIN; HEPARIN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; PLASMINOGEN;

ANTICOAGULATION; ARTICLE; BLEEDING; CASE REPORT; CENTRAL VENOUS CATHETER; CONTRAST ENHANCEMENT; DEEP VEIN THROMBOSIS; DOPPLER FLOWMETRY; FATALITY; HEMOPHILIA B; HUMAN; LIVER HEMORRHAGE; MALE; NEWBORN; PRIORITY JOURNAL; SUPERIOR CAVA VEIN SYNDROME; THALAMUS; THROMBOSIS; VEIN THROMBOSIS;

ANTICOAGULANTS; FACTOR IX; FATAL OUTCOME; HEMOPHILIA B; HEMORRHAGE; HUMANS; INFANT, NEWBORN; INTRACRANIAL THROMBOSIS; MALE;

EID: 16544391946     PISSN: 10774114     EISSN: None     Source Type: Journal    
DOI: 10.1097/00043426-200404000-00010     Document Type: Article

References (21)

1. Pollmann H, Richter H, Ringkamp H, et al. When are children diagnosed as having severe hemophilia and when do they start to bleed? A 10-year single-centre PUP study. Eur J Pediatr. 1999;158(Suppl 3):S166-S170.
2. Ljung R, Lindgren A-C, Petrini P, et al. Normal vaginal delivery is to be recommended for haemophilia carrier gravidae. Acta Paediatr. 1994;83:609-611.
3. Conway JH, Hilgartner MW. Initial presentations of pediatric hemophiliacs. Arch Pediatr Adolesc Med. 1994;148:589-594.
4. Kulkarni R, Lusher J. Perinatal management of newborns with haemophilia. Br J Haematol. 2001;112:264-274.
5. Le Pommelet C, Durand P, Laurian Y, et al. Hemophilia A: two cases showing unusual features at birth. Haemophilia. 1998;4:122-125.
6. Johnson-Robbins LA, Porter JC, Horgan MJ. Splenic rupture in a newborn with hemophilia A: case report and review of the literature. Clin Pediatr. 1999;38:117-119.
7. Olcay L, Gurgey A, Topaloglu H, et al. Cerebral infarct associated with factor V Leiden mutation in a boy with hemophilia A. Am J Hematol. 1997;56:189-190.
8. Ettingshausen CE, Martinez Saguer I, Kreuz W. Portal vein thrombosis in a patient with severe hemophilia A and F V G1691A mutation during continuous infusion of F VIII after intramural jejunal bleeding: successful thrombolysis under heparin therapy. Eur J Pediatr. 1999;158(Suppl 3):S180-S182.
9. Ritchie B, Woodman RC. Man-Chiu Poon. Deep venous thrombosis in hemophilia A. Am J Med. 1992;93:699-700.
10. Vidler V, Richards M, Vora A. Central venous catheter-associated thrombosis in severe haemophilia. Br J Haematol. 1999;104:461-464.
11. Journeycake JM, Quinn CT, Miller KL, et al. Catheter-related deep venous thrombosis in children with hemophilia. Blood. 2001;98:1727-1731.
12. Bjorkman S, Shapiro AD, Berntorp E. Pharmacokinetics of recombinant factor IX in relation to age of the patient: implications for dosing in prophylaxis. Haemophilia. 2001;7:133-139.
13. Hoffman C, Hultin MB. Factor IX concentrate therapy and thrombosis: relation to changes in plasma antithrombin III. Thromb Res. 1986;43:143-151.
14. Santagostino E, Mannucci PM, Gringeri A, et al. Markers of hypercoagulability in patients with hemophilia B given repeated, large doses of factor IX concentrates during and after surgery. Thromb Haemost. 1994;71:737-740.
15. Roth DA, Kessler CM, Pasi KJ, et al. Human recombinant factor IX: safety and efficacy studies in hemophilia B patients previously treated with plasma-derived factor IX concentrates. Blood. 2001;98:3600-3606.
16. Chowdary P, Dasani H, Jones JAH, et al. Recombinant factor IX (Benefix) by adjusted continuous infusion: a study of stability, sterility, and clinical experience. Hemophilia. 2001;7:140-145.
17. Hoots WK, Leissinger C, Stabler S, et al. Continuous infusion of a plasma-derived factor IX concentrate (Mononine®) in haemophilia B. Haemophilia. 2003;9:164-172.
18. van Hylckama Vlieg A, van der Linden IK, Bertina RM, et al. High levels of factor IX increase the risk of venous thrombosis. Blood. 2000;95:3678-3682.
19. Male C, Chait P, Ginsberg JS, et al. Comparison of venography and ultrasound for the diagnosis of asymptomatic deep vein thrombosis in the upper body of children. Thromb Haemost. 2002;87:593-598.
20. Chan AKC, Berry LR, Monagle PT, et al. Decreased concentrations of heparinoids are required to inhibit thrombin generation in plasma from newborns and children compared to plasma from adults due to reduced thrombin potential. Thromb Haemost. 2002;87:606-613.
21. DeVeber G, Chan A, Monagle P, et al. Anticoagulation therapy in pediatric patients with sinovenous thrombosis. Arch Neurol. 1998;55:1533-1537.